The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2022 | Novel promising agents and clinical trials in amyloidosis
In this video, Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN, discusses ongoing clinical trials in amyloidosis, sharing some insights into novel agents and the future treatment landscape of amyloidosis. First, Dr Dispenzieri discusses two trials that are investigating the use of CAEL-101, an antibody designed to remove AL amyloid deposits from tissues and organs, in patients with stage IIIa and IIIb disease. Dr Dispenzieri then discusses a trial investigating the use of birtamimab (NEOD001) to treat patients with stage IV disease, and the hope that novel immunotherapies used in the myeloma setting will eventually be used for the treatment of amyloidosis. To conclude, Dr Dispenzieri discusses the importance of monitoring cardiac biomarkers and considering toxicity when treating patients with amyloidosis, and the possibility of using venetoclax-based treatment approaches in amyloidosis. This interview took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.
